Kymera Therapeutics, Inc. $KYMR Shares Purchased by First Trust Advisors LP

First Trust Advisors LP boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 59.0% during the 1st quarter, HoldingsChannel reports. The firm owned 93,617 shares of the company’s stock after purchasing an additional 34,755 shares during the period. First Trust Advisors LP’s holdings in Kymera Therapeutics were worth $7,797,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. US Bancorp DE raised its holdings in shares of Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after buying an additional 166 shares during the last quarter. Larson Financial Group LLC boosted its stake in shares of Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after buying an additional 287 shares during the period. Swiss National Bank boosted its stake in shares of Kymera Therapeutics by 0.3% during the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock worth $7,871,000 after buying an additional 300 shares during the period. AlphaCentric Advisors LLC grew its holdings in shares of Kymera Therapeutics by 6.1% during the first quarter. AlphaCentric Advisors LLC now owns 5,342 shares of the company’s stock worth $445,000 after buying an additional 307 shares during the last quarter. Finally, Keudell Morrison Wealth Management grew its holdings in shares of Kymera Therapeutics by 5.9% during the first quarter. Keudell Morrison Wealth Management now owns 6,990 shares of the company’s stock worth $582,000 after buying an additional 390 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms have commented on KYMR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Friday, July 17th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Deutsche Bank Aktiengesellschaft started coverage on Kymera Therapeutics in a research note on Thursday. They issued a “hold” rating and a $120.00 target price on the stock. Truist Financial boosted their target price on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, Morgan Stanley restated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $124.48.

Insiders Place Their Bets

In other Kymera Therapeutics news, insider Noah Goodman sold 3,389 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $114.29, for a total transaction of $387,328.81. Following the completion of the transaction, the insider directly owned 47,179 shares in the company, valued at approximately $5,392,087.91. This trade represents a 6.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Nello Mainolfi sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at $79,321,592. This trade represents a 6.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,607,813 shares of company stock worth $387,818,004. 15.98% of the stock is owned by company insiders.

Kymera Therapeutics Stock Performance

KYMR opened at $103.40 on Friday. The company has a market cap of $8.51 billion, a price-to-earnings ratio of -28.96 and a beta of 1.95. Kymera Therapeutics, Inc. has a one year low of $36.65 and a one year high of $130.05. The business’s fifty day moving average is $98.92 and its two-hundred day moving average is $87.67.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same quarter last year, the business posted ($0.82) earnings per share. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, analysts predict that Kymera Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.